RT info:eu-repo/semantics/article
T1 Impact of COVID-19 on adherence to treatment in patients with HIV
A1 Carbonero Lechuga, Pablo
A1 Castrodeza Sanz, José Javier
A1 Sanz Muñoz, Iván
A1 Marqués Sánchez, Pilar
A1 Eiros Bouza, José María
A1 Dueñas Gutiérrez, Carlos Jesús
A1 Prada García, María del Camino
K1 HIV
K1 HIV infections
K1 AIDS (Disease)
K1 Sida
K1 Infectious diseases
K1 Virology
K1 Adherence
K1 Infecciones por VIH - Tratamiento
K1 COVID-19
K1 Antiretroviral agents
K1 SIDA (Enfermedad) - Tratamiento
K1 Enfermedades por virus - Tratamiento
K1 Public health
K1 Política sanitaria
K1 2420 Virología
K1 3205.05 Enfermedades Infecciosas
K1 3212 Salud Publica
AB In patients with human immunodeficiency virus (HIV), adherence to treatment is affected by the adverse effects of treatment, the presence of additional comorbidities, the complexity of dosage, and family and community support. However, one recent circumstance that was likely to have influenced therapeutic adherence was the COVID-19 pandemic and the applied containment measures. An observational retrospective study of a sample of patients with HIV was conducted to establish the relationship between sociodemographic, clinical, and pharmacological variables and therapeutic adherence before and after the pandemic. Adherence was measured using the validated simplified medication adherence questionnaire (SMAQ) and medication possession rate. A statistical analysis was performed to determine the mean, standard deviation, and median of the quantitative variables and the frequencies of the qualitative variables, and the relationship between the dependent and independent variables was analysed using the chi-squared test and Student’s t-test. No statistically significant differences were found between treatment adherence measured before and 22 months after the start of the pandemic. Sex, occupation, treatment regimen, viral load levels, and COVID-19 disease status did not influence adherence during either period. However, the age of patients with HIV had an impact on adherence during both periods (p = 0.008 and p = 0.002, respectively), with the age group under 45 years being less adherent. In addition, experiencing adverse drug reactions (ADRs) was shown to have an impact on adherence before the pandemic (p = 0.006) but not afterwards. The COVID-19 pandemic was not shown to have an impact on the degree of adherence to antiretroviral treatment in patients with HIV. Instead, adherence was influenced by patient age and ADR occurrence; therefore, measures must be taken in this regard. The SMAQ demonstrated sensitivity in assessing adherence.
PB MDPI
SN 2227-9032
YR 2023
FD 2023
LK https://uvadoc.uva.es/handle/10324/64368
UL https://uvadoc.uva.es/handle/10324/64368
LA eng
NO Healthcare, 2023, Vol. 11, Nº. 9, 1299
NO Producción Científica
DS UVaDOC
RD 24-nov-2024